Urology Devices Market By Product Type (Endoscopy Devices, Dialysis Equipment, Lithotripters, Prostate Devices (BPH Treatments), Catheters, Urodynamic Equipment, Others — Stents, Reconstruction), By Application (Kidney Disorders, Bladder Disorders, Prostate Conditions, Urinary Incontinence, Urological Cancer, Others), By Procedure (Diagnosis, Therapy, Surgery), By End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Home Care Settings), By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) and Companies — Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025–2035

Market Overview

The Global Urology Devices Market size is expected to be worth around US$ 77.38 Billion by 2035 from US$ 41.16 Billion in 2025, growing at a CAGR of 6.52% during the forecast period from 2026 to 2035. In 2025, North America led the market, achieving over 34% share with a revenue of US$ 13.99 Billion.

The Global Urology Devices Market is witnessing steady growth due to the rising burden of urological disorders, increasing geriatric population, and growing adoption of minimally invasive treatment technologies.

Urology devices include catheters, endoscopes, lithotripsy systems, urodynamic equipment, urinary stents, dialysis products, prostate treatment devices, and robotic-assisted surgical systems used for diagnosis, monitoring, and treatment of urinary tract and reproductive system conditions.

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) highlights that urological conditions such as urinary incontinence, kidney stones, urinary tract infections, and benign prostatic hyperplasia (BPH) affect millions of individuals and contribute significantly to healthcare needs.

The increasing prevalence of age-related urological conditions is a major factor supporting demand for advanced devices. According to NIDDK, BPH affects approximately 5%–6% of men aged 40–64 years and 29%–33% of men aged 65 years and older, creating a significant need for prostate management technologies.

Additionally, urinary incontinence remains a widespread concern, with NIDDK reporting that around 1 in 10 U.S. adults aged 18 years and older experience daily urinary incontinence.

Technological advancements are transforming the market through innovations such as robotic-assisted urological surgery, laser-based stone removal systems, digital endoscopy, AI-supported imaging, and single-use disposable instruments.

Regulatory agencies such as the U.S. Food and Drug Administration (FDA) classify and monitor a wide range of urological devices, including urinary catheters, diagnostic systems, and surgical instruments to ensure safety and effectiveness.

Growing healthcare infrastructure, increasing awareness of early diagnosis, and demand for minimally invasive procedures are expected to further accelerate adoption of urology devices across hospitals, specialty clinics, and ambulatory surgical centers worldwide.

Key Takeaways

• Market Size: The Global Urology Devices Market size was US$ 41.16 billion in 2025. The market is estimated to grow to US$ 77.38 billion by 2035.
• Market Share: The Compound Annual Growth Rate (CAGR) of the market from 2026 to 2035 will be 6.52%.
• Product Type: Endoscopy Devices (Ureteroscopes, Cystoscopes) has the largest market share, accounting for 18% of total product type revenue.
• Application: Kidney Disorders leads the segment, accounting for 28% of total application revenue.
• Procedure: Diagnosis leads the segment, accounting for 40% of total procedure revenue.
• End User: Hospitals lead the segment, accounting for 52% of total end-user revenue.
• Regional: North America is the dominant regional market, accounting for 34% of global revenue, holding US$ 13.99 billion in revenue in 2025.

Product Type Analysis

The product type segment of the Urology Devices Market is led by Endoscopy Devices (Ureteroscopes, Cystoscopes), which accounted for 18.0% market share in 2025. These devices maintain a leading position due to their widespread adoption in minimally invasive diagnostic and therapeutic procedures for urinary tract disorders, including kidney stones, bladder abnormalities, and ureteral conditions.

The increasing preference for smaller, flexible, and digital endoscopic systems is further supporting segment growth by improving visualization, accuracy, and patient outcomes.

Dialysis Equipment represented 16.0% market share in 2025, driven by the rising prevalence of chronic kidney disease, renal failure, and the growing need for renal replacement therapies. Lithotripters held a 15.0% share, supported by increasing demand for non-invasive kidney stone treatment procedures using shock wave and laser technologies.

Prostate Devices (BPH Treatments) captured 14.0% share, fueled by the growing burden of benign prostatic hyperplasia among aging male populations and adoption of minimally invasive therapies. Catheters accounted for 13.0%, owing to their essential role in urinary drainage and postoperative care.

Urodynamic Equipment contributed 12.0%, supporting diagnosis of bladder dysfunction and urinary disorders, while Others (Stents, Reconstruction) accounted for 12.0%, driven by applications in urinary tract repair and long-term patient management.

Application Analysis

The application segment of the Urology Devices Market is dominated by Kidney Disorders, which held the largest share of 28.0% in 2025. This dominance is attributed to the increasing global prevalence of kidney stones, chronic kidney disease, and renal complications requiring advanced diagnostic, therapeutic, and monitoring devices.

Rising adoption of lithotripsy systems, dialysis equipment, and minimally invasive procedures has significantly strengthened demand for urology devices targeting renal conditions.

Bladder Disorders represented 25.0% market share in 2025, supported by the growing incidence of urinary tract infections, bladder dysfunction, and overactive bladder conditions. Diagnostic cystoscopy, catheterization devices, and bladder management solutions continue to drive growth in this segment.

Prostate Conditions accounted for 20.0% share, primarily due to the increasing prevalence of benign prostatic hyperplasia (BPH) among older men and rising utilization of prostate treatment devices.

Urinary Incontinence captured 14.0% market share, supported by growing awareness of continence management solutions and advancements in implantable and minimally invasive treatment options.

Urological Cancer accounted for 9.0%, driven by increasing cases of bladder, kidney, and prostate cancers requiring diagnostic and surgical interventions. Others contributed 4.0%, including applications related to reconstructive procedures and less common urological conditions.

Procedure Analysis

The procedure segment of the Urology Devices Market is led by Diagnosis procedures, which accounted for 40.0% market share in 2025. Diagnostic procedures hold a significant position due to the increasing need for early detection and monitoring of urinary tract disorders, kidney diseases, prostate conditions, and urological cancers.

Technologies such as cystoscopy, ureteroscopy, urodynamic testing, and imaging-assisted diagnostic procedures are widely used to improve disease identification and treatment planning.

The Therapy segment represents a major growth area, supported by increasing adoption of minimally invasive treatments for kidney stones, urinary obstruction, prostate enlargement, and bladder disorders. Advanced devices such as laser lithotripters, prostate ablation systems, urinary stents, and catheter-based therapies are contributing to improved clinical outcomes and reduced recovery times.

The Surgery segment is also expanding due to the rising demand for advanced surgical interventions, including laparoscopic and robotic-assisted urological procedures. Increasing investments in surgical technologies, improved visualization systems, and precision-based instruments are enhancing procedural efficiency.

Overall, the shift toward minimally invasive approaches, shorter hospital stays, and improved patient outcomes is accelerating adoption across diagnostic, therapeutic, and surgical applications within the urology devices landscape.

End-User Analysis

The end-user segment of the Urology Devices Market is dominated by Hospitals, which accounted for 52.0% market share in 2025. Hospitals represent the largest end-user category due to their advanced infrastructure, availability of specialized urology departments, and ability to perform complex diagnostic, therapeutic, and surgical procedures.

High patient volumes for kidney disorders, urinary tract conditions, prostate diseases, and urological cancers continue to drive demand for advanced urology devices in hospital settings.

Ambulatory Surgical Centers (ASCs) represent a growing segment, supported by the increasing shift toward outpatient minimally invasive procedures. ASCs offer cost-effective treatment options, reduced hospitalization periods, and faster recovery, making them increasingly preferred for procedures such as stone removal, endoscopic interventions, and prostate treatments.

Specialty Clinics are expanding due to their focused expertise in urological care, early diagnosis, and chronic disease management. These facilities increasingly adopt compact diagnostic systems and specialized treatment devices to provide targeted patient care.

Home Care Settings are gaining importance, particularly for patients requiring long-term urinary management, dialysis support, and continence care. Growth in home-based healthcare models, aging populations, and improved portable medical technologies are supporting adoption of urology devices outside traditional healthcare facilities.

Key Market Segments

By Product Type

• Endoscopy Devices (Ureteroscopes, Cystoscopes)
• Dialysis Equipment
• Lithotripters
• Prostate Devices (BPH Treatments)
• Catheters
• Urodynamic Equipment
• Others (Stents, Reconstruction)

By Application

• Kidney Disorders
• Bladder Disorders
• Prostate Conditions
• Urinary Incontinence
• Urological Cancer
• Others

By Procedure

• Diagnosis
• Therapy
• Surgery

By End User

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Home Care Settings

Drivers

Minimally invasive BPH and endoscopic stone management adoption

Minimally invasive treatment is lifting growth because it shortens recovery, reduces hospital dependency, and broadens the treatable pool among patients who delay conventional surgery but accept lower-burden intervention.

NCBI documents that surgical management of BPH has broadened materially beyond TURP into laser vaporization, holmium laser enucleation, prostatic urethral lift, water-vapor therapy, microwave thermotherapy, balloon dilation, and selected embolization approaches, which means the market is no longer dependent on a single incumbent modality.

This diversification matters strategically instead of competing only on console placement, manufacturers can capture value through fibers, implants, access sheaths, scopes, baskets, guidewires, irrigation, and post-procedure catheter products, creating repeatable revenue across high-frequency benign disease workflows.

Because symptomatic thresholds are well defined, AUA/IPSS symptom score treatment often begins at 10 or higher, pathological PVR is commonly above 200 mL, and peak urinary flow below roughly 13 mL/s supports obstructive workup, the decision pathway into intervention is increasingly protocolized, which supports faster adoption of technologies that show lower anesthesia burden, shorter turnover time, and cleaner outpatient economics.

Challenges

Reimbursement Gaps and Limited Value Evidence Slow Adoption

Reimbursement misalignment and gaps in robust real-world value evidence create a roughly 1.0 %-point drag on the urology devices market, as payers in major markets scrutinize incremental device costs more tightly than in the 2000s and early 2010s.

In the U.S., for example, CMS and commercial payers have been cautious about granting significant incremental payments for new disposable scopes or premium implants when DRG payments for procedures like TURP, ureteroscopy, or cystectomy have grown more slowly than hospital input costs, squeezing contribution margins by 100–200 basis points in many health systems and encouraging substitution toward reusable devices or generic implants when possible.

In Europe and Japan, HTA bodies often demand 3–5 years of outcomes data and cost-utility analyses showing gains of at least 0.1–0.2 QALYs or meaningful reductions in re-operation rates before granting higher tariffs or including devices on reimbursement lists, which slows uptake of innovations such as new urethral stricture technologies or novel incontinence therapies; this evidence generation timeline can lag regulatory approval by 24–48 months, during which penetration may remain trapped below 10–15% of the target population.

Strategically, manufacturers must invest heavily, often 5–8% of sales, into post-market registries, pragmatic clinical trials, and payer-specific budget-impact models that track endpoints like 30-day readmission rates, catheterization duration, and long-term retreatment rates.

They also need to embed economic modeling capabilities early in R&D so that design choices explicitly target cost drivers such as procedure time, consumables re-use, and management of complications.

Without this pivot to payer-centric, outcomes-linked value narratives, even clinically superior devices will continue to face slower formulary addition, narrower coverage policies, and higher rates of prior authorization, all of which operate as friction rather than outright bans but still materially reduce annual growth.

Restraints

Post-Recall Scrutiny Delays Urology Device Adoption and Growth

The urology device market has adopted a more conservative outlook following repeated recalls involving implants, catheters, and endoscopic systems. Evidence from 510(k) safety research indicates that devices relying on problematic predicates face substantially higher recall risks, increasing portfolio concerns across high-volume categories such as ureteroscopes, catheters, and slings.

Hospitals have consequently strengthened value-analysis and procurement reviews, with additional committee cycles and longer evaluation periods delaying new installations and extending replacement timelines. For manufacturers, stricter scrutiny is increasing pre-market and post-market evidence requirements, including studies and registry participation, thereby raising lifecycle costs.

Companies with previous safety actions may also face higher warranty provisions and product-liability insurance expenses, placing further pressure on profitability. Collectively, these factors are expected to weaken urology device unit economics, reduce EBIT margins, and slow equipment replacement rates.

Accordingly, a conservative 1.5-percentage-point reduction in achievable global CAGR over a four-year-or-longer period is justified as manufacturers redesign products and healthcare systems adopt longer replacement cycles.

Opportunity

Emerging Market Day-Surgery Expansion Boosts Urology Device Demand

Emerging-market day-surgery and mid-tier urology center expansion constitutes a long-term opportunity because current forecasts often extrapolate device adoption from high-income markets and underweight the buildout of ambulatory and mid-tier facilities in regions where both urologic disease burden and population growth are highest.

Global incident cases of urolithiasis exceeded 115 million in 2019 with rising absolute numbers despite declining age-standardized rates, and BPH prevalence among men over 60 continues to grow at more than 100% increase over three decades, with the highest prevalence in Eastern Europe and parts of Latin America and Asia, yet many countries still lack adequate procedure capacity and dedicated urology centers.

As governments and private operators in APAC emerging economies, LATAM, the Middle East, and Africa invest in day-surgery infrastructure, urology devices, endoscopy, lithotripsy, stents, and catheters can shift from centralized tertiary hospitals to distributed networks that perform high-volume, lower-acuity interventions at 20%–30% lower procedural cost, unlocking previously latent demand among middle-income patients.

If these regions increase urologic procedure rates by 25%–35% by 2035 through enabling day-surgery models and expanding mid-tier centers, with device ASPs tailored to mid-market budgets, for example, 15%–20% lower prices but higher volumes.

The incremental TAM could reach USD 6–9 billion on top of existing projections and drive a 200–300 basis point margin uplift through localized manufacturing and simplified product platforms, contributing an estimated 2.1 % points upside to global CAGR over the long term.

Regional Analysis

In 2025, North America led the market, achieving over 34% share with a revenue of US$ 13.99 billion. The region’s leadership is supported by a high prevalence of chronic kidney disease, benign prostatic hyperplasia (BPH), urinary incontinence, and urological cancers, creating sustained demand for advanced diagnostic and therapeutic devices.

Well-established healthcare infrastructure, favorable reimbursement systems, and widespread adoption of minimally invasive and robotic-assisted urological procedures further strengthen market growth. Continuous investments in medical technology, the presence of leading device manufacturers, and increasing utilization of digital endoscopy, laser lithotripsy, and advanced catheter systems also contribute to regional dominance.

Europe represents the second-largest regional market, driven by an aging population, expanding healthcare expenditure, and increasing awareness regarding early diagnosis and treatment of urinary tract disorders. Strong regulatory standards, growing adoption of minimally invasive surgical techniques, and modernization of hospital infrastructure continue to support demand across major European countries.

The Asia-Pacific region is expected to witness the fastest growth during the forecast period. Rising healthcare investments, improving access to specialized urology services, expanding hospital networks, and increasing prevalence of kidney stones and chronic kidney diseases are accelerating market expansion. Growing medical tourism and rising adoption of advanced medical technologies further enhance regional opportunities.

Meanwhile, Latin America and the Middle East & Africa are experiencing steady market growth, supported by improving healthcare infrastructure, increasing government healthcare initiatives, expanding access to diagnostic services, and rising awareness of urological disease management.

Although these regions currently account for smaller market shares, continued healthcare modernization and investments are expected to create significant long-term growth opportunities.

Key Regions and Countries

North America

• The US
• Canada

Europe

• Germany
• France
• The U.K.
• Italy
• Spain
• Russia & CIS
• Rest of Europe

Asia Pacific

• China
• India
• Japan
• South Korea
• ASEAN
• Australia & New Zealand
• Rest of Asia Pacific

Middle East & Africa

• GCC
• South Africa
• Rest of Middle East & Africa

Latin America

• Brazil
• Mexico
• Rest of Latin America

Key Player Analysis

Suppliers in the global urology devices market are strengthening their competitive positions through innovations in digital ureteroscopes, cystoscopes, and minimally invasive BPH treatment systems.

Advanced endoscopic platforms are being developed to deliver higher image resolution, improved deflection, and reduced infection risks through single-use designs compared with reusable alternatives. Robotic-assisted surgical platforms, including Intuitive Surgical’s da Vinci system, are expanding clinical applications across radical prostatectomy, nephrectomy, and cystectomy.

Companies are also expanding single-use flexible endoscope portfolios for stone management and upper urinary tract diagnostics while developing home hemodialysis systems to support patient-administered treatment outside dialysis centers.

Investments are increasingly focused on visualization technologies, surgeon training, proctorship programs, and clinical-economic evidence packages to support hospital value analysis and procurement decisions.

In parallel, population aging, rising prevalence of BPH, urinary incontinence, kidney stones, and urological cancers, and growing adoption of minimally invasive procedures are expected to sustain institutional demand through 2035.

Top Key Players

• Boston Scientific Corporation
• Olympus Corporation
• KARL STORZ SE & Co. KG
• Becton, Dickinson and Company (BD)
• Coloplast A/S
• Medtronic plc
• Intuitive Surgical Inc.
• Richard Wolf GmbH
• Fresenius Medical Care AG
• Stryker Corporation
• Cook Medical LLC
• Siemens Healthineers AG
• Other Key Players

Recent Developments

• In January 2026, Boston Scientific Corporation launched its next-generation single-use digital flexible ureteroscope with enhanced 4K imaging resolution and extended deflection capability, targeting hospital urology department and ambulatory surgical center institutional buyers seeking infection risk elimination and superior stone visualization performance.
• In February 2026, Olympus Corporation expanded its endourology device portfolio with an enhanced reusable digital cystoscope platform featuring improved chip-on-tip imaging technology, securing institutional procurement agreements with leading European hospital urology department and specialty clinic buyers.
• In March 2026, Medtronic plc received FDA clearance for its next-generation aquablation robotic BPH treatment system featuring enhanced real-time ultrasound imaging guidance, targeting hospital urology department institutional buyers seeking improved tissue selectivity and functional outcome preservation in surgical BPH management.
• In May 2026, Fresenius Medical Care AG expanded its home hemodialysis equipment portfolio across North American and European home care institutional distribution channels, targeting chronic kidney disease patients and nephrology clinic institutional buyers seeking patient-administered home dialysis therapy alternatives to center-based treatment.

Report Scope